What is the recommended intramuscular (IM) dose of midazolam in children?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 6, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Intramuscular Midazolam Dosing in Pediatric Patients

For intramuscular sedation in children, the recommended dose is 0.1-0.15 mg/kg, with higher doses up to 0.5 mg/kg used for more anxious patients, though the total dose typically should not exceed 10 mg. 1

Age-Specific IM Dosing Recommendations

The FDA-approved dosing for intramuscular midazolam varies by age and clinical context 1:

  • Standard sedation dose: 0.1-0.15 mg/kg is usually effective and does not prolong emergence from general anesthesia 1
  • Anxious patients: Doses up to 0.5 mg/kg have been used safely 1
  • Maximum total dose: Generally does not exceed 10 mg 1

Age-dependent dosing for premedication shows that younger children require higher mg/kg doses 2:

  • Under 3 years: 0.5 mg/kg 2
  • 3-10 years: 0.4 mg/kg 2
  • 10-15 years: 0.25 mg/kg 2

Clinical Effectiveness and Onset

IM midazolam produces age and dose-dependent sedation, with higher doses resulting in deeper and more prolonged sedation 1. The anxiolytic effect is excellent in over 85% of cases across all age groups when appropriate weight-based dosing is used 2.

However, IM midazolam at 0.4 mg/kg does not effectively sedate combative children requiring restraint for procedures, though it does produce reliable amnesia 3. For highly anxious or combative children requiring procedural sedation, low-dose IM ketamine (2.5 mg/kg) remains more effective than midazolam 3.

Critical Safety Considerations

When midazolam is co-administered with opioids or other sedatives, the initial dose of each medication must be reduced due to increased risk of respiratory depression, airway obstruction, and hypoventilation 1.

Pediatric patients under 6 months are particularly vulnerable to airway obstruction and hypoventilation, requiring titration with small increments and careful monitoring 1. Limited safety data exists for this age group 1.

Continuous monitoring of oxygen saturation and respiratory status is mandatory 4, and respiratory support equipment must be immediately available 4.

Route Comparison

IM administration is more effective than intranasal midazolam for achieving adequate sedation levels 5. In a comparative study, IM midazolam (0.2 mg/kg) provided statistically better sedation and less movement at venipuncture compared to intranasal administration 5.

Common Pitfalls to Avoid

  • Do not calculate doses based on total body weight in obese children—use ideal body weight instead 1
  • Do not exceed 10 mg total dose in most clinical scenarios 1
  • Do not use higher doses without understanding the trade-off—doses above 0.15 mg/kg may prolong sedation and increase hypoventilation risk 1
  • Be prepared for paradoxical agitation, particularly in younger children 4

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.